
Opinion|Videos|December 5, 2024
Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab
Panelists discuss the common toxicities associated with trifluridine-tipiracil plus bevacizumab in clinical practice, including their typical severity, and share their strategies for managing dose reductions and interruptions due to cytopenias when treating patients with this regimen.
Advertisement
Episodes in this series

- Let’s further discuss these agents’ safety profiles and management strategies.… Dr Fakih, could you please discuss common toxicities that clinicians may see with trifluridine-tipiracil plus bevacizumab in their day-to-day practice?
- What is the usual severity?
- What is your treatment strategy in terms of dose reduction and/or interruptions due to cytopenias with trifluridine-tipiracil plus bevacizumab?
Advertisement
Related to this article

The FDA approved giredestrant plus everolimus in ESR1-mutated breast cancer and neladalkib in ALK+ NSCLC, issued a CRL to ivonescimab, and more.

Daraxonrasib plus gemcitabine/nab-paclitaxel yielded a 60.7% ORR and 12.8-month median PFS in first-line metastatic pancreatic adenocarcinoma.

Sac-TMT improved OS vs treatment of physician’s choice in pretreated gastroesophageal adenocarcinoma, but TroFuse-015 missed its PFS secondary end point.

Gynecologic oncologists answer FAQs on LGSOC targeted therapy, PARP inhibitor maintenance, and emerging ADCs in ovarian cancer.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Jorge Cortes, MD, discusses response-based ponatinib dosing, mutation testing, and managing cardiovascular risk in resistant CML.
Advertisement
Advertisement
Trending on OncLive
1
Daraxonrasib Plus Gemcitabine/Nab-Paclitaxel Generates Durable Responses in First-Line Metastatic PDAC
2
TroFuse-015 Meets Primary OS End Point With Sac-TMT in Third-Line or Later Gastroesophageal Adenocarcinoma
3
Dr Iyengar on Oral SERD Implementation in Early-Stage HR+ Breast Cancer
4
Dr Gutierrez on Considerations for Investigating SAR445877 in MSS CRC
5


